Wells Fargo raised the firm’s price target on Stericycle to $48 from $40 and keeps an Underweight rating on the shares. While encouraged by early results, Wells Fargo remains cautious on the 13%-17% EBITDA growth ramp, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SRCL:
- Stericycle price target raised to $62 from $50 at Baird
- Stericycle reports Q4 adjusted EPS 54c, consensus 47c
- Stericycle, Inc. Reports Results For The Fourth Quarter 2023
- SRCL Earnings this Week: How Will it Perform?
- Stericycle to Present at Raymond James 45th Annual Institutional Investors Conference in March
